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Because of expanding indications and improvements in supportive care, the utilization of blood and marrow
cell transplantation (BMT) to treat various conditions is increasing exponentially, and currently more than
60,000 BMTs are performed annually worldwide. By the year 2030, it is projected that the number of BMT
survivors will increase 5-fold, potentially resulting in one half of a million survivors in the United States alone.
As the majority of survivors now live beyond the ﬁrst 2 years after BMT, they are prone to a unique set of
complications and late effects. Until recently, BMT experts assumed responsibility for almost all of the care for
these survivors, but now oncologists/hematologists, pediatricians, and internists are involved frequently in
offering specialized care and preventive services to these survivors. To integrate and translate into clinical
practice the unique BMT survivorship issues with current preventive guidelines, a team effort is required. This
can be facilitated by a dedicated “long-term-follow-up (LTFU)” clinic that provides lifelong care for BMT
survivors. In this review, we ﬁrst illustrate with clinical vignettes the need for LTFU and then focus upon the
following: (1) types of LTFU clinic models, (2) challenges and possible solutions to the establishment of LTFU
clinic, and (3) vulnerable transition periods.
 2015 American Society for Blood and Marrow Transplantation.INTRODUCTION
The term cancer survivor typically refers to any individual
who has been diagnosed with cancer, and the journey of
survivorship begins at diagnosis and includes all curative and
palliative treatments [1]. Similarly, we deﬁne blood and
marrow transplantation (BMT) survivor as any individual who
has undergone a BMT, with BMT survivorship beginning on
the day of transplantation (day 0 of stem cell infusion).
Because of the expanding indications for BMT and im-
provements in supportive care leading to decreased mor-
tality [2], the use of BMT for treating various malignant and
nonmalignant diseases is increasing exponentially [3].
Currently, more than 60,000 BMTs are performed annually
worldwide. It is projected that the number of BMT survivors
will increase 5-fold, to a total of 500,000 by the year 2030 in
the United States alone [4].dgments on page 231.
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2 years after BMT, they are prone to a unique set of compli-
cations and late effects that reﬂect the complex interplay
between their cancer diagnosis (or their immune/genetic
disorder), prior immunotherapies and/or chemotherapies,
conditioning therapy, and graft-versus-host disease (GVHD).
This leads to a multitude of changes in physical, psycholog-
ical, ﬁnancial, and social domains. Let’s now consider, as an
example, 1 of 2 BMT survivors.
Peter, a widowed 55-year-old male information technol-
ogy specialist with acute lymphoblastic leukemia in second
complete remission, was conditioned immediately before
transplantation with 12 Gy total body irradiation (TBI)
and cyclophosphamide and then infused with a related
peripheral blood stem cell allograft. Because of multiple
pretransplantation relapses, his cumulative anthracycline
exposure now totals a substantial 450 mg/m2. He is 2 years
after BMT and has developed severe uncontrolled dyslipi-
demia and advanced chronic GVHD, for which he is being
treated with corticosteroids, cyclosporin, statins, and pro-
phylactic antibiotics. He lives alone in New York City and is
unable to use his computer because of GVHD-associatedTransplantation.
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his quality of life.
The second survivor is Rong, a 19-year-old Vietnamese
woman who underwent BMT at age 13 for marrow failure
associated with Fanconi anemia. She was conditioned with
2 Gy TBI and ﬂudarabine and then infused with bone
marrow. She recently underwent neck dissection for oral
cancer and is struggling with depression. Before BMT, Rong
received multiple red cell transfusions and now has
abnormal liver function that is presumably due to iron
overload. She lives with her very supportive parents in rural
western United States and believes in the curative potential
of Chinese herbal medications for all ailments.
Although these patients differ with respect to age, socio-
demographic proﬁle, and current medical conditions, they
each demonstrate several late effects that can characterize
BMT survivorship. The common late effects range from TBI-
associated hypothyroidism (with up to 20% of survivors
eventually becoming hypothyroid after full-dose TBI) [5];
ﬁnancial burden including unemployment [6]; post-
traumatic stress disorder [7,8]; cutaneous carcinomas
(mainly due to BMT conditioning, but GVHD is an additional
risk factor) [9,10]; cataracts (mainly due to TBI, but steroid
exposure increases this risk) [11]; and metabolic syndromes
(mainly due to BMT, but immunosuppressive therapy is an
additional risk factor) [12], as well as many other complica-
tions (particularly infections). However, certain risks are
more speciﬁc to each of these patients.
Peter’s risk of heart failure and coronary artery disease is
substantial [13,14] because of his exposure to TBI, anthracy-
clines, and because of metabolic syndrome, including
medication-induced diabetes and hypertension. His chronic
GVHD has been signiﬁcantly disabling because of deep fas-
ciitis, which has severely restricted the range of motion in his
wrists and ankles. He also remains at risk of lung cancer due
to BMT [15] and a history of cigarette smoking; suicide, due
to BMT and loneliness [16]; chronic kidney disease due to
cyclosporin, GVHD, and diabetes [17]; and osteoporosis, due
to complications of glucocorticoids [18,19]. He requires
extensive services from physiatry, especially occupational
therapy for musculoskeletal GVHD; clinical psychology, to
evaluate for psychiatric comorbidities; cardiology and
nephrology, for late effects surveillance; and endocrinology,
to consult on the management of iatrogenic diabetes, bone
health, and secondary adrenal insufﬁciency. Dermatology
and ophthalmology are consulted for skin cancers and
cataract screening, respectively. Social workers are often
called to provide essential additional support relevant to
their expertise. Individualized care plans are the overall goal
of coordinated long-term follow-up. Lastly, the struggle with
chronic GVHD as an orphan disease for which no FDA-
approved therapies exist often delays the recovery for a
number of BMT survivors like Peter.
For Rong, 6 years after BMTat a young age, the risk of new
head and neck cancers remains extremely high as a conse-
quence not only of BMT but also as a result of her underlying
Fanconi anemia [20,21]. Infertility primarily due to TBI
[22-24] and complications due to secondary hemochroma-
tosis [25,26] are other very relevant late effects. Because her
post-transplantation survival is expected to be high, Rong’s
lifetime risk for developing a conditioning treatmente
related myeloid neoplasm is considerably higher than
Peter’s. An individualized multidisciplinary approach for
Rong will include the services of psychology, hepatology,
gynecology, and dermatology. In addition to ongoingmonitoring for suicidal ideation and sexual dysfunction, she
will be offered well-deﬁned interval screening for hepa-
tomas, breast cancer, cervical cancer, head and neck cancers,
and skin cancers. She will also see complementary and
alternative medicine experts to discuss the pros and cons of
their suggested therapies because she behaves similarly to
the 90% of cancer survivors who utilize complementary and
alternative medicine for a variety of symptoms [27-29]. She
still wants to continue seeing her primary transplantation
physician, a pediatric hematologist, but at some future time
point, her care will typically be transitioned to an adult
provider or a long-term follow-up (LTFU) clinic that provides
care to adult BMT survivors.
Each 1 of these survivors is very illustrative of the need for
well-coordinated multidisciplinary care to help optimize
BMT outcomes. Such care is possible only through collabo-
rations between BMT experts, physicians, and allied health
professionals (AHP) in the ﬁelds of oncology, hematology,
pediatrics, and internal medicine. Collaborations often need
to span long distances because a sizeable proportion of sur-
vivors do not live close to the BMT center. Thus, it is impor-
tant for all relevant academic and community-based
clinicians to understand the basics of late effects [30], coor-
dination of care models, and the role of an organized clinic
that is dedicated to providing specialized care to these sur-
vivors to optimize the long-term beneﬁts of BMT.
Late effects in cancer literature are deﬁned as complica-
tions arising months to years after cancer treatment is over
[31]. Speciﬁc late effects preventive guidelines have been
published for BMT survivors [32]. Other areas of BMT survi-
vorship continue to be actively studied, particularly caregiver
health [33-35], quality of life with GVHD [36-38], psycho-
social burden [39-41], integration of caremodels [42,43], and
health care utilization/ﬁnancial toxicity [6,44,45]. To inte-
grate aforementioned BMT survivorship issues and current
preventive guidelines into clinical practice, a team effort, that
can be facilitated by a dedicated LTFU clinic that follows BMT
survivors lifelong, is required.
Although the data on late effects in BMT survivors are
rapidly accumulating, research on the value of LTFU clinics
for this population is lacking. In this review, we highlight the
following: (1) basics of LTFU clinic models, (2) challenges
faced in establishing LTFU clinics and proposed solutions;
and (3) vulnerable transition periods in BMT survivorship
longitudinal care.
LONG-TERM FOLLOW-UP CLINIC MODELS
Compared with a 5-decade history of BMT [46], the ﬁeld
of BMT survivorship is still in its infancy. The Children’s
Oncology Group has assimilated comprehensive guidelines
on childhood cancer survivors, which include risk-adapted
management guidance for speciﬁc late effects [47]. The
Children’s Oncology Group has also described various LTFU
models of care for pediatric cancer survivors. BMT survivors’
needs differ from those of general cancer survivors, as
illustrated by the cases of Peter and Rong: they can easily
overwhelm the management capacity of a single health care
provider. Comprehensive care requires speciﬁc knowledge
and expertise of late (>6 months after BMT) and very
late effects (>5 years after BMT) due to a multitude of
physical and psychological insults before, during, and after
transplantation.
Dedicated LTFU clinics are operational at a minority of the
centers that currently perform BMT; models of care differ by
center as described below and in Table 1. We do not propose
Table 1
Hematopoietic Stem Cell Transplant Survivor Clinic Models
Clinic Model Advantages Disadvantages
Cancer survivorship integrated model
(No strictly deﬁned interval of
post-HSCT duration for inclusion)
Initiation is relatively easy given the already
existent cancer survivorship clinic
Dedicated GVHD experts may not be available to
evaluate all HSCT patients
May have extensive collaborations with various
specialties for both cancer and HSCT care
More intense utilization of resources and time for
clinical and supportive services may not be
affordable
Excellent systems in place for systems-based
practice with community clinicians
Lack of knowledge of late effects of HSCT survivors
of nonmalignant diseases eg, hemoglobinopathies,
bone marrow failure syndromes
Chronic GVHD and survivorship LTFU
(may start at 6 mo-2 yr after HSCT)
Expert management for chronic GVHD and its
complications available
Appropriate resources for core specialties
established (ophthalmology, dermatology,
physiatry, psychology, and gynecology)
More emphasis on GVHD than on very late effects
Occasional patients early on after HSCT may relapse
(leukemia relapses can happen even 3 yr after HSCT)
and will be excluded from this clinic
Currently, many such models are separate for adults
and pediatric survivors
HSCT survivorship LTFU (usually
2 yr after HSCT eligible)
Expert management for chronic GVHD and its
complications available
Excellent resources for early detection of very
late complications (eg, coronary heart disease)
Logistically hard to establish, unless a large
transplantation program
HSCT indicates hematopoietic stem cell transplantation.
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model may change over time, according to the needs and
experiences of that center.Cancer Survivorship Integrated Model
Within this model, the BMT clinic is 1 of several survi-
vorship clinics caring for survivors of various types of cancers
under the large umbrella of cancer care. Many cancer survi-
vor clinics incorporate the services of primary care clinicians
to provide preventive and surveillance services to cancer
survivors. After being transitioned to this model, a survivor’s
future care is primarily dictated by this clinic’s team, with
little contribution from the original BMT or primary hema-
tology/oncology team. This model is more popular for the
care of pediatric rather than adult survivors.BMT LTFU Models
This model is independent of general cancer survivorship
clinics and has dedicated teams focusing on improving the
health of only BMT survivors.
For allogeneic BMT recipients, late complications occur
more frequently than they do for autologous transplantation
survivors. Chronic GVHD may cause major issues for alloge-
neic BMT survivors. LTFU clinics are designed to provide
long-term care speciﬁcally to BMT survivors, who have no
evidence of relapse of the primary disease. Traditionally, a
BMT survivor follows up annually in the LTFU clinic lifelong
and sees many consultants from different specialties.
Generally, this comprehensive annual visit ends with a
“wrap-up session,” during which results of these evaluations
are discussed and care recommendations are made.
Two philosophies of care provision exist for the dedicated
LTFU BMT model: (1) chronic GVHD and (2) survivorship
LTFU (hybrid). Hybrid GVHD and survivorship LTFU clinics
generally provide comprehensive treatment strategies for
the management of GVHD. Here, collaborating specialists
have a keen interest in GVHD complications. Proponents of
this type of LTFU model believe that GVHD and survivorship
issues cannot be separated, as chronic GVHD is the most
common cause of comorbidities in survivors of allogeneic
BMT.
Pure survivorship LTFU clinics generally have a greater
focus on late and very late effects, including psychological,social, and pathological aspects of survivors. Such clinics
typically seek survivors who are at least 2 or more years after
BMT so that the risk of primary disease is minimal. The
emphasis is on early detection of potential late effects that
could arise because of GVHD or non-GVHD related compli-
cations, eg, aggressive screening for coronary artery disease.
Survivorship-only clinics also have a particular focus on the
unique needs of autologous transplantation survivors and
may have algorithms developed for disease-based groups.
Thus, for example, lymphoma survivors who received chest
or neck irradiation may additionally undergo regular
screening with carotid artery ultrasounds. Survivorship LTFU
clinics commonly involve primary care physicians and AHPs
with speciﬁc interest in survivorship issues to provide
routine preventive care at deﬁned intervals.CHALLENGES AND CONSIDERATIONS FOR ESTABLISHING
BMT LTFU CLINICS
In the United States alone, there are at least 200 BMT
centers, most of which have an afﬁliation with a cancer
center. As the number of BMTs is growing dramatically
worldwide, institutional leaders and clinicians are focusing
on trying to establish dedicated LTFU survivorship clinics.
Some of the important considerations, challenges, and pro-
posed solutions are described below (and highlighted in
Table 2).Systems Capacity in BMT
As the number of BMTs performed in both the United
States and outside continues to upsurge, it is anticipated that
the demand for transplantation-trained specialists will likely
outpace the need. A recent report utilizing data from the
National Donor Marrow Program indicated that from 2005 to
2009, the total number of allogeneic BMTs increased by 30%,
BMT bed capacity increased by 17%, and BMT physician full-
time equivalents increased by 26%; however, but the ma-
jority of transplantation centers were performingmore BMTs
despite unchanged physician number and bed capacity [48].
Well-trained transplantation physicians and AHPs with a
keen interest in BMT survivorship issues are critical to the
successful initiation of BMT LTFU clinics. The “System Ca-
pacity Initiative Physician Workforce Group” of the National
Donor Marrow Program is aggressively working to identify
Table 2
Challenges in Establishment of an LTFU Clinic and Potential Solutions
Challenges Description Solutions
Systems capacity issue Lack of HSCT experts to run LTFU clinic Convincing institutional leadership of the need for establishment
of an LTFU clinic requiring HSCT experts
NMDP Physician Workforce Group working on potential solutions
for recruitment/retention of HSCT physicians in this ﬁeld
Responsibility designation Who is responsible for delivery of preventive
servicesdprimary care/pediatrics or HSCT
experts?
LTFU clinic experts should be able to provide almost all preventive
services for HSCT survivors
If unable, then designate the primary care/pediatric teams for
preventive care with effective communication
Ancillary/administrative
services
Frequently resources unavailable for some
ancillary/administrative services
Identify key priorities of HSCT survivors and utilize the currently
available resources
Involve the administrative staff, billing staff, appointment staff, IT
staff in early phases of establishment of LTFU clinic
Starting up LTFU Absence of guidance of a typical HSCT LTFU
clinic set up
No hard and fast rule of initial setup of LTFU clinic and dependent
on resources and needs
A proposed algorithm for set up, which may be helpful, is given
in Table 2
Survivorship care plan
(SCP)
HSCT SCPs unavailable Development of SCP based on HSCT-speciﬁc issues and also
resources available at the institution
Can consider modifying the already existent SCPs of other cancers
NMDP indicates National Marrow Donor Program; IT, information technology.
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tion of transplantation physicians in this ﬁeld [49].
In the current era of ﬁscal restraints of health care de-
livery, it may be impractical for some institutions to hire
employees to serve the needs of BMT survivors unless the
immediate and long-term beneﬁts of this expanded work-
force are clearly delineated. Convincing institutional leader-
ship of the need for establishing an LTFU clinic is a crucial
ﬁrst step, for which the long-term rewards must be
explained (“Rewards and Functional Section” section below,
and Figure 1). Operational team roles have to be deﬁned at all
levels (Figure 2).
Responsibility Designation
The 3 major stakeholders in the health care delivery
model for BMT survivors include the BMT team, local he-
matologist/oncologist, and the primary care physician/pedi-
atrician. The role of each key player in providing care to the
hematopoietic cell transplantation survivor is unclear at this
time. In the Survey of Physician Attitudes Regarding the Care
of Cancer Survivors study, forms were mailed out in to a
nationally representative sample of US primary care physi-
cians and medical oncologists, and results indicated that
oncologists were likely to report uncertainty regarding
general preventive care responsibility [50]. It is important to
deﬁne roles clearly to avoid duplication of efforts and elim-
inate the redundancy in care process to optimize efﬁciency.
Additionally, the transition to an LTFU clinic should be dis-
cussed by the primary BMT physician in detail with BMT
survivors before designating responsibility of care to LTFU
clinic team so that the survivors are comfortable with the
transition to ensure continuity of care.
Ancillary/Administrative Services
It is important to involve the key players whowill provide
ancillary services to BMT survivors. This includes radiolo-
gists, occupational and physical therapists, laboratory staff,
and administrative staff in the areas of billing, scheduling,
and transportation and housing services. For transplantation
centers where some of these services are not available,
establishing collaborations with other nearby centers (eg, for
physical therapy) is advisable before setting up a BMT LTFU
clinic. In certain smaller BMT centers (eg, if number ofhematopoietic stem cell transplantations performed <50
annually, then a new dedicated hematopoietic stem cell
transplantations LTFU clinic may not be feasible and an in-
tegrated model within a cancer survivorship clinic may
sufﬁce).
Absence of Guidance for Setup of an LTFU Clinic
Because a typical LTFU clinic setup involves many spe-
cialties and subspecialties and additionally requires signiﬁ-
cant monetary resources, no ideal setup is known. However,
we present a step-by-step guide for establishing an LTFU
clinic, which may help some centers in startup of a new
program, as shown in Figure 1.
Establishing BMT-speciﬁc Survivorship Care Plans
In 2006, the US Institute of Medicine recommended that
each cancer patient receive an individualized “survivorship
care plan (SCP)” including guidelines for monitoring and
maintaining his or her health [1]. American Society of Clinical
Oncology has created SCP templates for survivors of various
cancers [51]. For BMT survivors, similar SCPs can be created
andmodiﬁed according to institutional resources. In addition
to the chemotherapy and radiotherapy received before
transplantation, the BMT SCPs may include all trans-
plantations (if applicable), donor information, conditioning
regimen, and GVHD prophylaxis. Many BMT LTFU clinics
improve real-time communication and coordination by
providing updated SCPs to each survivor at each visit and
also by mailing a new copy to their local providers.
REWARDS AND FUNCTION ESSENTIALS
It has been reported that establishment of an LTFU clinic
may improve overall survival in BMT survivors [52]. In
addition, geographic distance from a clinic has not been
found to have an association with inferior outcomes if pa-
tients are followed in a BMT-speciﬁc LTFU clinic [53]. These
reports highlight outcomes-based need for establishment of
LTFU clinic. Extensive data are available on the rewarding
outcomes of preventive care in the general populationwhere
screening for early detection of cancers has shown to prevent
mortality [46,54]; thereby, various organizations have
formulized recommendations for cancer screening at regular
intervals for at-risk populations.
Figure 1. Step-by-step guide for establishing a long-term follow-up clinic for hematopoietic stem cell transplantation survivors.
S. Hashmi et al. / Biol Blood Marrow Transplant 21 (2015) 225e232 229In BMT survivors, whose risk of developing secondary
cancers is signiﬁcantly higher than those in the general
population [9,10,20], vigilant screening for early detection of
cancers requires systematic preventive services. Prevention
of 1 case of cancer by early detection in BMT survivors canlead to substantial cost savings [55,56]. For example, the risk
of lung cancer is elevated in BMT survivors compared with
the general population [15], for which the national guide-
lines recommending low-dose CT scan (ages 55 to 80 years,
30 pack-year smoking) [57]. Screening for lung cancer in
Figure 2. Operational team of long-term follow-up clinic for stem cell transplantation survivors. LTFU: Long Term Follow Up; IT: Information Technology; CAM:
Complementary and Alternative Medicine; HSCT: Hematopoietic Stem Cell Transplant; GVHD: Graft Versus Host Disease. *LTFU core teammay include any one or more
of the specialties. **Consultative specialties may include any number of collaborating specialties depending on the resources available. *** Medical Photography for
joint and skin photographs for all survivors (especially for allogeneic HSCTs), as baseline even in the absence of GVHD. { In some countries, the head of Dept. of Internal
Medicine or Hematology leads the HSCT division/dept. {{May include physicians or allied health professionals (e.g. nurse practitioners or physician assistants).
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way. Blindness prevention is another example. Vision pres-
ervation is top priority of many public health efforts because
visual loss is 1 of the leading causes of compromised quality-
adjusted life years and disability-adjusted life years [58-60].
Including an ophthalmologist/optometrist as part of an LTFU
clinic team to screen all BMT survivors for cataracts and
ocular GVHD, and to offer early treatment for these condi-
tions, can help prevent blindness in survivors. These type of
services may be cost saving and may keep many patients
from requiring disability services.
The essential elements of such a clinic include provision
of both treatment and preventive services to BMT survivors
lifelong at deﬁned intervals, incorporating individualized
planning for issues unique to survivors. To achieve this in a
systematic fashion, services rendered by a single clinician
interested in BMT survivorship may be inadequate and co-
ordinated care from multiple specialties with time linee
based clinical algorithms is necessary. An example of
detailed services to be coordinated with various specialties is
given in Figure 1.
VULNERABLE TRANSITIONS
In the absence of relapse and active GVHD, most BMT
survivors may eventually require transition to another set of
providers. Ideally, this should be accomplished seamlessly
through good communication and coordination. However,
the vulnerabilities and complexities of such transitions of
care have become evident, and medical and/or psychological
crises may emerge or resurface among certain groups of
patients who are at risk being lost in transition.
Pediatric Transition to Adulthood
Children and adolescents with cancer or other disease
amenable to BMT grow up within a unique context of living
arrangements and receive medical care within an equallycomplex, interlocking set of relationships that might include
social workers, psychologists, and primary hematologist/
oncologists. These BMT survivors and their families may have
difﬁculty leaving the protective environment created by pe-
diatric caregivers. Therefore, it is not uncommon for pedi-
atric BMT survivors in their thirties and forties to continue
seeing their pediatric caregivers. Absence of well-deﬁned
care transition plans has also been reported to pose obsta-
cles for the transfer to adult providers, highlighting the
observation that regular follow-up often ceases when these
patients leave pediatric care [61-63].
An ideal LTFU clinic design might include both adult and
pediatric clinicians, although so far the segregation of adult
and pediatric services has not facilitated such a design
model. An example of the potential beneﬁt of an LTFU clinic
staffed by pediatric and adult providers might be that man-
agement of late effects, such as cardiovascular complications
and certain secondary cancers (eg, lung cancer), might sit
more comfortably with the adult rather than pediatric pro-
vider. Another design element might specify that pediatric
transplantation social workers are an integral part of the
LTFU clinic team, who, through their history of patient and
family rapport at earlier times of stress, can facilitate conti-
nuity of care during the transition period. Psychosocial and
ﬁnancial (insurance) stressors would also be discussed in
detail with survivors during this transition.
Elderly Patients
The median age at which BMTs are being performed is
increasing [2] because of greater use of reduced-intensity
and nonmyeloablative conditioning regimens. Because
many patients are now receiving BMT after age 65, the
complicated needs of long-term survivors within this cohort
of patients might beneﬁt from consultation with geriatri-
cians and, sometimes, palliative care experts. Advance care
planning is particularly relevant to this group and requires a
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plications so that survivors can better prepare for future
decisions about their medical treatments and end-of-life
care [64]. Septuagenarians and octogenarians might also
beneﬁt from a comprehensive geriatric assessment, deﬁned as
a multidisciplinary management process that identiﬁes
medical, psychosocial, and functional limitations of a survi-
vor [65]. Comprehensive geriatric assessments can result in
practical end-products, such as fall prevention plans and
advanced care plans.
Transplantation Across International Boundaries
Technological globalization is outpacing economic glob-
alization, resulting in a growth of international travel for
receipt of transplants. The awareness of transplantation in-
dications and cancer treatments has risen dramatically in
developed and developing countries across all human
development indices, increasing the number of patients
getting BMTs across borders. The density of transplantation
centers is dependent on a country’s human development
index and many countries do not have BMT programs [66].
Although organ trafﬁcking and transplantation tourism
(typically from developed world to developing countries)
may be responsible for 5% to 10% of the kidney trans-
plantations globally [67]; in the BMTmanagement paradigm,
the issue is opposite. An unrelated allogeneic BMT in the
United States usually costs more than $200,000 for the ﬁrst
month of transplantation [68], whereas a kidney trans-
plantation usually costs <$20,000 (consumer price index-
eadjusted) from related live donors in developing countries
[69]. Many patients from developing countries travel to
developed countries at great cost to receive BMT from a
related or unrelated donor because of the absence of BMT
facilities in their native countries.
The requirements of a near hospital stay after BMT within
a geographically deﬁned radius of a transplantation center
vary by each center. This issue needs to be clearly discussed
with international BMTsurvivors for expected complications.
Additionally, clinicians caring for international patients
should be sensitive to the cultural, religious, and social as-
pects of these patients and additionally aware of ﬁnancial
constraints of traveling patients and their families. Although
most patients are informed about BMT costs before travel,
the long-term survivorship care costs are typically not dis-
cussed in detail with the survivors and data on how these
services may be covered in various countries are absent;
thus, before leaving the country at which BMT was per-
formed, this aspect of long-term prevention of late effects
should be discussed with the survivors in detail.
A typical LTFU clinic setup requires BMT survivors to visit
the clinic annually. Many patients, who cannot afford to visit
the developed countrywhere they received the transplant on
an annual basis, are at risk of developing late effects. Before
an international patient leaves the transplantation center
after BMT, communication via e-mail or phone should be
established with the local transplantation physician or
oncologist/hematologist in the country of origin.
FUTURE DIRECTIONS
Understanding the onset and course of late effects is
important to provide timely interventions as an attempt to
reduce the risk of developing late effects and related
morbidity and mortality after BMT. Therefore, signiﬁcant
resources should be focused on better implementation of
how patients and clinicians use extensive data regardingpost-transplantation late complications in clinical care.
We recommend early referral or discussion with a trans-
plantation/cancer center for enrollment of patient in avail-
able late effect studies and for management guidelines.
Long-term survivors should be assessed lifelong after BMT;
all health care providers involved in the follow-up of these
patients should be aware of the preventable premature
health threats of long-term complications after trans-
plantation. We believe that all of these goals to can be
accomplished by well-trained LTFU clinical staff at trans-
plantation/cancer center.
Additionally, we encourage professional societies
involved with hematology and BMT to convince national
authorities to support establishment of dedicated clinics for
BMT survivors, including complete insurance coverage for
treatment and preventive services. We hope that an increase
in the establishment of BMT survivorship clinics in the near
future will provide tremendous help in preventing many late
complications that are unique to BMTsurvivors, such as Peter
and Rong, so that they are not “lost in transition.”ACKNOWLEDGMENTS
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